Milestone Pharmaceuticals stock holds at $1.16 as fundamentals and outlook stay in focus
Published on 08/29/2026 at 13:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Milestone Pharmaceuticals Inc. (US60041A1025) stock is quoted at $1.16 as of August 28, 2026, with the shares down 42.6 percent year-to-date from $2.02 at the start of 2026. Recent market data also show investors digesting the latest quarterly loss and limited revenue base as the company progresses its lead cardiovascular candidate.
Share performance and valuation context
According to market statistics for MIST, Milestone Pharmaceuticals stock closed at $1.16 on August 28, 2026, down 2.52 percent on the day. The same overview indicates that the stock started 2026 at $2.02, so the current level represents a 42.6 percent decline since the beginning of the year, underscoring ongoing volatility around clinical and regulatory milestones.
The same source cites an estimated next earnings date of November 11, 2026, and lists Milestone Pharmaceuticals in the healthcare sector under the pharmaceuticals industry with a Nasdaq listing under the symbol MIST. For investors, this positions the company among smaller development-stage biopharma names where news on trials, regulatory feedback, or partnership activity can quickly change sentiment.
Latest reported fundamentals and earnings picture
The latest quarterly figures highlighted in the earnings snapshot show that Milestone Pharmaceuticals reported a loss per share of $0.21 in its most recent quarter, compared with a consensus expectation of a $0.20 loss per share. That represents an underperformance versus expectations by $0.02 per share, reinforcing the company’s profile as a loss-making, R&D-focused issuer.
On the top line, the same quarterly release is summarized with revenue of $0.56 million for the period, compared with analyst estimates of $0.82 million. This means actual revenue was $0.26 million below the estimate, highlighting the limited but growing contribution from collaboration or early commercialization activities while the core value driver remains the clinical pipeline.
The company’s earnings calendar in that overview flags the last earnings event on August 12, 2026, which falls within the current reporting season for companies with a December 31 fiscal year-end. With the fiscal year ending December 31, 2026, the recent quarter provides the most current snapshot of spending and revenue trends, and it will be closely compared with the expected update in November 2026.
How the fundamentals frame the risk-reward
The combination of a $0.21 loss per share in the latest quarter and revenue of $0.56 million underlines that Milestone Pharmaceuticals is still firmly in an investment phase, financing clinical development rather than generating substantial product sales. Because the reported revenue fell short of the $0.82 million estimate, investors may be focusing more on the company’s cash runway and trial timelines than on near-term earnings metrics.
From a performance perspective, the 42.6 percent year-to-date decline in the share price from $2.02 to $1.16 suggests that market expectations have reset during 2026 as new information on progress and spending emerged. For some investors, the gap between the current price and prior levels may reflect concern about dilution risk or the timing of value-creating catalysts, while others may read it as a sign that a significant portion of execution risk is now embedded in the valuation.
Because Milestone Pharmaceuticals operates in a segment where binary events are common, each quarterly result, even with modest revenue and a negative EPS, also serves as a check-in on whether the company is pacing its development spending in line with its funding capacity. The recent miss versus both EPS and revenue expectations adds another data point for assessing how tightly management is guiding investor expectations.
Etripamil and the cardiovascular focus
Milestone Pharmaceuticals has built its strategy around developing fast-acting cardiovascular therapies, with its lead product candidate etripamil targeted at providing rapid relief in certain cardiac arrhythmias. While the detailed clinical data are not laid out in the same market snapshot, the company’s public materials and prior communications have consistently framed etripamil as a nasal-spray therapy designed to be used in out-of-hospital settings.
For shareholders, the commercial opportunity around etripamil is central: successful late-stage trials and regulatory approval could open a niche but meaningful market in acute care cardiology, where patients and physicians value speed of symptom relief. Conversely, any delays or negative outcomes in key studies would quickly overshadow short-term movements in quarterly revenue, because most of the company’s current value stems from expectations about this asset’s future cash flows.
Stock positioning going into the next catalyst
With Milestone Pharmaceuticals stock at $1.16 as of the August 28, 2026 close, the shares trade at a fraction of the levels seen at the start of 2026, when they stood at $2.02. That compression in market value over a relatively short period underscores how sensitive development-stage biotech valuations are to shifts in perceived probability of success, financing conditions, and sector sentiment.
Looking ahead to the next expected earnings update in November 2026 as indicated in the company calendar, investors will likely focus on updated cash balances, operating expense trends, and any fresh commentary on regulatory or partnership discussions. For Milestone Pharmaceuticals, demonstrating disciplined spending while advancing etripamil and any follow-on assets will remain the key to rebuilding confidence in the stock.
Representative product: etripamil for episodic arrhythmias
Etripamil, Milestone Pharmaceuticals’ lead investigational drug, is designed as a rapid-onset therapy that patients with certain episodic arrhythmias could potentially self-administer to manage sudden episodes outside of a hospital. That concept aims to reduce emergency room visits and improve quality of life by shortening the duration and severity of attacks, subject to successful trial outcomes and regulatory approval.
MIST stock at a glance
As of the August 28, 2026 Nasdaq close cited in recent market data, Milestone Pharmaceuticals stock trades at $1.16 under the ticker MIST in USD. The current level, down 42.6 percent from $2.02 at the start of 2026, frames the shares as a high-risk, event-driven biotech position where upcoming clinical and earnings milestones will likely drive the next significant move.
Fact box
Company: Milestone Pharmaceuticals Inc.
ISIN: US60041A1025
Ticker: MIST
Exchange: Nasdaq
Price (as of August 28, 2026, 4:00 p.m. ET): $1.16 USD
Sector / Industry: Healthcare / Pharmaceuticals
Next earnings date: November 11, 2026
